Jeff Garro
Stock Analyst at Stephens & Co.
(0.68)
# 4,102
Out of 5,147 analysts
58
Total ratings
25.64%
Success rate
-14.62%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DH Definitive Healthcare | Maintains: Equal-Weight | $3 → $2 | $1.28 | +56.25% | 2 | Feb 27, 2026 | |
| CERT Certara | Maintains: Overweight | $15 → $12 | $7.08 | +69.49% | 6 | Dec 12, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $32 | $23.75 | +34.74% | 6 | Dec 4, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $20 → $17 | $7.58 | +124.27% | 4 | Nov 17, 2025 | |
| EVH Evolent Health | Reiterates: Equal-Weight | $9 | $3.25 | +176.92% | 6 | Sep 24, 2025 | |
| PHR Phreesia | Reiterates: Overweight | $32 | $12.33 | +159.53% | 9 | Sep 3, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $28 → $20 | $12.23 | +63.53% | 2 | Jul 15, 2025 | |
| TBRG TruBridge | Reiterates: Equal-Weight | $28 | $19.29 | +45.15% | 3 | Apr 10, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $182.01 | +53.84% | 2 | Mar 6, 2025 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $7 → $5 | $1.62 | +208.64% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $55 | $24.53 | +124.22% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $250 | $178.81 | +39.81% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $18.18 | -6.49% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $5.26 | +432.32% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $19.22 | +4.06% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $8.96 | -56.47% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.86 | +248.80% | 3 | May 6, 2022 |
Definitive Healthcare
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.28
Upside: +56.25%
Certara
Dec 12, 2025
Maintains: Overweight
Price Target: $15 → $12
Current: $7.08
Upside: +69.49%
Privia Health Group
Dec 4, 2025
Reiterates: Overweight
Price Target: $32
Current: $23.75
Upside: +34.74%
OptimizeRx
Nov 17, 2025
Maintains: Equal-Weight
Price Target: $20 → $17
Current: $7.58
Upside: +124.27%
Evolent Health
Sep 24, 2025
Reiterates: Equal-Weight
Price Target: $9
Current: $3.25
Upside: +176.92%
Phreesia
Sep 3, 2025
Reiterates: Overweight
Price Target: $32
Current: $12.33
Upside: +159.53%
Simulations Plus
Jul 15, 2025
Maintains: Overweight
Price Target: $28 → $20
Current: $12.23
Upside: +63.53%
TruBridge
Apr 10, 2025
Reiterates: Equal-Weight
Price Target: $28
Current: $19.29
Upside: +45.15%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $182.01
Upside: +53.84%
Health Catalyst
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.62
Upside: +208.64%
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $24.53
Upside: +124.22%
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $178.81
Upside: +39.81%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $18.18
Upside: -6.49%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $5.26
Upside: +432.32%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $19.22
Upside: +4.06%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $8.96
Upside: -56.47%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $0.86
Upside: +248.80%